Imaging study for people with high-risk leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early (Phase 1) study tests how a special scan works in people with relapsed or hard-to-treat leukemia types. The scan uses a tracer called 18F FLT, and the study looks to see if it can be done safely (without sedation) and how it relates to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 4 to 80 (or the parent/guardian is participating for a child).
- You have high-risk leukemia that has come back or isn’t responding (such as acute lymphocytic leukemia or acute myeloid leukemia, etc.).
- You can do the scan while awake (no sedation) and can tolerate the 18F FLT imaging.
- Your general health tests are within limits (oxygen levels >90% without oxygen; and liver/kidney blood tests not too high).
- You can use effective birth control during the study if you are age-appropriate; the study requires you are not pregnant or breastfeeding.
- You (or a parent/guardian) can understand the study and give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study uses special whole-body imaging scans (PET with CT, plus MRI) to look for signs of acute myeloid leukemia outside the bone marrow. It may help doctors better see where leukemia is and guide future care.
This trial tests a new approach: giving a targeted radioactive antibody (attached to a drug that finds CD38 on cancer cells) along with low-dose chemotherapy and targeted radiation to the bone marrow before a donor stem cell transplant. The goal is to prepare the body for the transplant while killing remaining cancer cells more precisely.
This trial tests a new combination of medications against a standard treatment for adults with a specific type of acute myeloid leukemia (AML) that has a FLT3-ITD mutation. The goal is to find out if the new combination works better and has fewer side effects. If you have this type of AML, you might be able to join and get access to newer drugs.
This early-phase study tests how well a special PET-MRI scan (using a radioactive tracer) can find and measure low-grade brain tumors. It may help doctors better track these tumors while you start or continue treatment.
This trial tests a new PET/CT imaging tracer called [18F]BL40 to see if it can help spot certain types of blood cancers. It may help doctors better understand and monitor these diseases.
This trial uses a special imaging agent called 68Ga-EV203 to see where certain blood cancers (multiple myeloma, non-Hodgkin lymphoma, or acute myeloid leukemia) are located in the body. It helps doctors understand how the agent spreads and how safe it is.
Hear when a new Acute Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.